silybin has been researched along with guaifenesin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, KS; Kim, JH; Kim, JS; Kwon, OK; Oh, SR; Park, JW; Shin, IS; Shin, NR | 1 |
| Chen, H; Feng, N; He, Y; Hou, X; Liu, Y; Shen, J; Shi, J; Wang, Z; Xie, X | 1 |
2 other study(ies) available for silybin and guaifenesin
| Article | Year |
|---|---|
Silibinin Inhibits Neutrophilic Inflammation and Mucus Secretion Induced by Cigarette Smoke via Suppression of ERK-SP1 Pathway.
Topics: Animals; Extracellular Signal-Regulated MAP Kinases; Inflammation; Male; Mice; Mice, Inbred C57BL; Mucus; Neutrophils; Phosphorylation; Plants, Medicinal; Reactive Oxygen Species; Signal Transduction; Silybin; Silymarin | 2016 |
Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Caco-2 Cells; Cell Movement; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mucus; Nanoparticles; Neoplasms, Experimental; Phenanthrenes; Rats, Sprague-Dawley; Silybin; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |